<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.wjso.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>World Journal of Surgical Oncology - Latest Articles</title>
        <link>http://www.wjso.com</link>
        <description>The latest research articles published by World Journal of Surgical Oncology</description>
        <dc:date>2013-06-18T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.wjso.com/content/11/1/142" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/11/1/141" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/11/1/140" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/11/1/139" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/11/1/138" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/11/1/137" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/11/1/136" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/11/1/135" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/11/1/134" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/11/1/133" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.wjso.com/content/11/1/142">
        <title>Ovarian granulosa cell tumors: a retrospective study of 27 cases and a review of the literature</title>
        <description>Background:
Granulosa tumors were described for the first time in 1855 by Rokitansky. These tumors are malignancies with a relatively favorable prognosis. They are characterized by a prolonged natural history and a tendency to late recurrences. The aim of this study is to investigate the epidemiological and pathological characteristics of granulosa cell tumors and to investigate the prognosis factor for recurrences.
Methods:
The clinical data of patients who were treated in the period from January 2003 to December 2010 at the National Institute of Oncology in Rabat, Morocco for adult granulosa cell tumors of the ovary were investigated retrospectively. Data for age, clinical manifestation, imaging, diagnosis and treatment of the patients were reviewed and analyzed. Post-operative histology was obtained for all patients.
Results:
Twenty-seven cases were retrieved. The median patient age was 53 years. The most common clinical manifestations at diagnosis were abdominal pain and vaginal bleeding. Mean tumor size was 14 cm.The majority of patients had stage I (63%, n = 17), while (18,5%, n = 5) had stage III, (7.4%, n = 2) had stage IV, and (11%, n = 3) of patients had an unknown stage.In the follow-up period (median = 63.44 months), five (18.51%) patients relapsed. The median time to relapse was 41.8 months, (range: 18 to 62 months).
Conclusions:
Granulosa cell tumor of the ovary is an uncommon neoplasm. The adult form progresses slowly and often is diagnosed in an early stage of disease. Surgery is indicated. A prolonged post-therapeutic follow-up is necessary because of the risk of recurrences, late and exceptional for the adult form.</description>
        <link>http://www.wjso.com/content/11/1/142</link>
                <dc:creator>Sakina Sekkate</dc:creator>
                <dc:creator>Mouna Kairouani</dc:creator>
                <dc:creator>Badr Serji</dc:creator>
                <dc:creator>Adnane Tazi</dc:creator>
                <dc:creator>Hind Mrabti</dc:creator>
                <dc:creator>Saber Boutayeb</dc:creator>
                <dc:creator>Hassan Errihani</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2013, null:142</dc:source>
        <dc:date>2013-06-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-11-142</dc:identifier>
                                <prism:require>/content/figures/1477-7819-11-142-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>142</prism:startingPage>
        <prism:publicationDate>2013-06-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/11/1/141">
        <title>Overexpression of HSPA2 is correlated with poor prognosis in esophageal squamous cell carcinoma</title>
        <description>Background:
Heat shock-related 70 kDa protein 2 (HSPA2) has been identified as a potential cancer-promoting protein expressed at abnormal levels in a subset of cancers. However, its important role in esophageal squamous cell carcinoma (ESCC) is hardly known by people. The purpose of this study is to assess HSPA2 expression and to explore its role in ESCC.
Methods:
Thirty ESCC samples, paired adjacent non-cancerous tissues and normal esophageal tissues, were collected for HSPA2 detection by quantitative RT-PCR (qRT-PCR) and western blotting. Additionally, the expression of HSPA2 in ESCC and adjacent non-cancerous tissues from 120 patients was analyzed by immunohistochemistry, and correlated with clinicopathological parameters and patients&apos; outcome.
Results:
HSPA2 mRNA and protein were overexpressed in ESCC tissues. Overexpression of HSPA2 was significantly associated with primary tumor, TNM stage, lymph node metastases and recurrence, respectively (all, P &lt;0.05). Kaplan-Meier curves showed that elevated HSPA2 expression was associated with shorter disease-free survival and overall survival in ESCC patients. Cox multivariate regression analysis revealed that overexpression of HSPA2 was an independent prognostic factor in disease-free survival and overall survival for ESCC patients (hazard ratio was 2.115 and 2.210, respectively, P &lt;0.05).
Conclusions:
Our findings demonstrate that overexpression of HSPA2 may contribute to the malignant progression of ESCC and present a novel prognostic indicator for ESCC patients.</description>
        <link>http://www.wjso.com/content/11/1/141</link>
                <dc:creator>Hang Zhang</dc:creator>
                <dc:creator>Wei Chen</dc:creator>
                <dc:creator>Chao-Jun Duan</dc:creator>
                <dc:creator>Chun-Fang Zhang</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2013, null:141</dc:source>
        <dc:date>2013-06-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-11-141</dc:identifier>
                                <prism:require>/content/figures/1477-7819-11-141-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>141</prism:startingPage>
        <prism:publicationDate>2013-06-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/11/1/140">
        <title>Does geography influence the treatment and outcomes of colorectal cancer? A population-based analysis</title>
        <description>Background:
The Canadian province of Manitoba covers a large geographical area but only has one major urban center, Winnipeg. We sought to determine if regional differences existed in the quality of colorectal cancer care in a publicly funded health care system.
Methods:
This was a population-based historical cohort analysis of the treatment and outcomes of Manitobans diagnosed with colorectal cancer between 2004 and 2006. Administrative databases were utilized to assess quality of care using published quality indicators.
Results:
A total of 2,086 patients were diagnosed with stage I to IV colorectal cancer and 42.2% lived outside of Winnipeg. Patients from North Manitoba had a lower odds of undergoing major surgery after controlling for other confounders (odds ratio (OR): 0.48, 95% confidence interval (CI): 0.26 to 0.90). No geographic differences existed in the quality measures of 30-day operative mortality, consultations with oncologists, surveillance colonoscopy, and 5-year survival. However, there was a trend towards lower survival in North Manitoba.
Conclusion:
We found minimal differences by geography. However, overall compliance with quality measures is low and there are concerning trends in North Manitoba. This study is one of the few to evaluate population-based benchmarks for colorectal cancer therapy in Canada.</description>
        <link>http://www.wjso.com/content/11/1/140</link>
                <dc:creator>Ramzi Helewa</dc:creator>
                <dc:creator>Donna Turner</dc:creator>
                <dc:creator>Debrah Wirtzfeld</dc:creator>
                <dc:creator>Jason Park</dc:creator>
                <dc:creator>David Hochman</dc:creator>
                <dc:creator>Piotr Czaykowski</dc:creator>
                <dc:creator>Harminder Singh</dc:creator>
                <dc:creator>Emma Shu</dc:creator>
                <dc:creator>Lin Xue</dc:creator>
                <dc:creator>Andrew McKay</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2013, null:140</dc:source>
        <dc:date>2013-06-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-11-140</dc:identifier>
                                <prism:require>/content/figures/1477-7819-11-140-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>140</prism:startingPage>
        <prism:publicationDate>2013-06-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/11/1/139">
        <title>Pure mucinous carcinoma of the breast: clinicopathologic characteristics and long-term outcome among Taiwanese women</title>
        <description>Background:
Pure mucinous carcinoma (MC) is found in about 3.5% of all newly diagnosed breast cancer patients in Taiwan. MC is a relatively rare malignancy of breast cancer, and its nature, behaviors, treatment pattern and long-term follow-up are not well understood. The study aimed to investigate the incidence rate, treatment patterns, and prognostic factors of MC of the breast and the clinical long-term outcomes compared with infiltrating ductal carcinoma not otherwise specified (IDC) in the middle and south Taiwanese women.
Methods:
Data from 93 patients with breast MC were retrospectively reviewed and the clinicopathologic characteristics and survival status were compared with those of 2,674 patients with IDC.
Results:
The expression of hormonal receptor was higher in MC than those in IDC (P &lt;0.001). MC also demonstrated lower Her2/neu gene over-expression (P = 0.023), less axillary lymph node involvement (P &lt;0.0001), lymphovascular invasion (P &lt;0.0001) and higher 10-year overall survival rate (P = 0.042), when compared with those of IDC.
Conclusion:
Our data confirm the less aggressive behavior of MC compared to IDC. MC showed favorable clinicopathologic characteristics in tumor grade, hormone receptor status and lymph node involvement in the middle and south Taiwanese women.</description>
        <link>http://www.wjso.com/content/11/1/139</link>
                <dc:creator>Hsin-Shun Tseng</dc:creator>
                <dc:creator>Che Lin</dc:creator>
                <dc:creator>Szu-Erh Chan</dc:creator>
                <dc:creator>Su-Yu Chien</dc:creator>
                <dc:creator>Shou-Jen Kuo</dc:creator>
                <dc:creator>Shou-Tung Chen</dc:creator>
                <dc:creator>Tsai-Wang Chang</dc:creator>
                <dc:creator>Dar-Ren Chen</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2013, null:139</dc:source>
        <dc:date>2013-06-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-11-139</dc:identifier>
                                <prism:require>/content/figures/1477-7819-11-139-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>139</prism:startingPage>
        <prism:publicationDate>2013-06-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/11/1/138">
        <title>Focused abdominal ultrasound in preoperative liver surgery staging: a prospective study</title>
        <description>Background:
Because of its safety, relative low cost and widespread availability, conventional ultrasound (US) is the modality of choice for initial evaluation of the liver. Following US, in patients eligible for surgery, further computed tomography and/or magnetic resonance imaging is usually recommended for surgical planning. There are no recent published series focusing on conventional abdominal US exclusively employed for the evaluation of liver nodules before surgery. The objective of this study is to evaluate the efficacy of focused conventional preoperative US in detecting liver lesions, and the impact of US findings on surgical management.
Methods:
Sixty-seven noncirrhotic patients underwent surgical resection, after being previously submitted to focused liver US evaluation. US results were compared with intraoperative US (IOUS) and histology (gold standard). The IOUS was performed by the same radiologist who performed the preoperative US. Patient-by-patient and lesion-by-lesion analyses were performed.
Results:
A total of 241 lesions were depicted in 67 patients. The mean number of lesions detected per patient by US and IOUS was 2.37 and 3.37, respectively (P = 0.001). In 52.2% of patients, US and IOUS depicted the same number of liver lesions. Surgery with curative intent was conducted in 61 (91.0%) patients. Histological evaluation was obtained in 196 lesions; 155 were considered malignant. The overall lesions detection rate by US was 65.6%. For lesions &lt;15 mm and lesions &gt;=15 mm, US showed a sensitivity rate of 55.3% and 75.5%, respectively.
Conclusions:
The relatively high sensitivity rates achieved by US focused on liver evaluation, with the aim of lowering costs but not efficiency, places the method in focus again for use in the routine preoperative staging of candidates for liver resection. We suggest for preoperative evaluation that US could be associated with one section imaging method (computed tomography or magnetic resonance imaging) as routine.</description>
        <link>http://www.wjso.com/content/11/1/138</link>
                <dc:creator>Marcela Cohen</dc:creator>
                <dc:creator>Paulo Herman</dc:creator>
                <dc:creator>Rubens Chojniak</dc:creator>
                <dc:creator>Miriam Poli</dc:creator>
                <dc:creator>Paula Barbosa</dc:creator>
                <dc:creator>Almir Bitencourt</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2013, null:138</dc:source>
        <dc:date>2013-06-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-11-138</dc:identifier>
                                <prism:require>/content/figures/1477-7819-11-138-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>138</prism:startingPage>
        <prism:publicationDate>2013-06-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/11/1/137">
        <title>The estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumors</title>
        <description>Background:
The aim of the study was to evaluate the concentration of proteolytic enzymes, MMP-2 and MMP-9, and their tissue inhibitors, TIMP-1 and TIMP-2, in the blood of patients with benign and malignant pancreatic tumors.
Methods:
MMP-2, MMP-9, TIMP-1, and TIMP-2 were evaluated in the patients with benign and malignant pancreatic tumors before surgery and in the 30-day follow-up. The study covered 134 patients aged 54 to 76 years, who were divided into groups by TNM staging.
Results:
Before the operation, the highest mean concentration of MMP-2 was found in patients with unresectable cancer, whereas the highest level of MMP-9 was in patients with resectable cancer. The highest level of TIMP-1 was noted in patients with inflammatory tumors. In 1 month following the operation, the highest level of MMP-2 was also in patients with unresectable cancer and the highest level of TIMP-2 in patients with inflammatory tumors.
Conclusions:
The evaluation of the level of the studied cytokines in the pancreatic tumor patients can be diagnostically significant in the differentiation of benign and malignant changes. The changes in the levels of the studied enzymes and their inhibitors can have a prognostic value in the clinical severity of pancreatic cancer.</description>
        <link>http://www.wjso.com/content/11/1/137</link>
                <dc:creator>Jacek ¿migielski</dc:creator>
                <dc:creator>¿ukasz Piskorz</dc:creator>
                <dc:creator>Renata -Wojnarowska</dc:creator>
                <dc:creator>Ewa Malecka-Panas</dc:creator>
                <dc:creator>S¿awomir Jab¿o¿ski</dc:creator>
                <dc:creator>Marian Brocki</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2013, null:137</dc:source>
        <dc:date>2013-06-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-11-137</dc:identifier>
                                <prism:require>/content/figures/1477-7819-11-137-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>137</prism:startingPage>
        <prism:publicationDate>2013-06-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/11/1/136">
        <title>The expression of cytokeratin 19 in lymph nodes was a poor prognostic factor for hepatocellular carcinoma after hepatic resection</title>
        <description>Background:
The expression of CK19 in primary hepatocellular carcinoma (HCC) is associated with a poor outcome. However, few studies have investigated the expression profile of CK19 in regional lymph nodes (LNs) of HCC after hepatic resection. The purpose of this study was to evaluate the expression of CK19 in primary liver tumor and regional LNs of HCC with and without lymph node metastasis (LNM).
Methods:
The expression of CK19 in patients with (n = 16) and without LNM (n = 26) was examined using immunohistochemical staining. Both the primary tumor and LN specimen were studied for their CK19 expression. Clinico-pathological variables and prognostic significance were analyzed.
Results:
Immunopositivity of CK19 in primary liver tumor was significantly correlated with LNM (P = 0.005) and tumor non-encapsulation (P &lt;0.005). Univariate analysis showed that CK19 expression in primary liver tumor, CK19 expression in regional LN, vascular invasion, daughter nodules, positive resection margin and American Joint Committee on Cancer (AJCC) tumor stage significantly decreased overall survival. Multivariate analysis demonstrated that daughter nodules (P = 0.001) and CK19 expression in regional LN (P = 0.002) were independent prognostic factors for overall survival.
Conclusions:
This study showed that CK19 expression in regional LN of HCC was associated with LNM and an extremely poor outcome after operation. It is of clinical significance to identify these patients at risk for more aggressive HCC, and multi-modality treatment could be helpful to improve their dismal outcome.</description>
        <link>http://www.wjso.com/content/11/1/136</link>
                <dc:creator>Chao-Wei Lee</dc:creator>
                <dc:creator>Wen-Ling Kuo</dc:creator>
                <dc:creator>Ming-Chin Yu</dc:creator>
                <dc:creator>Tse-Ching Chen</dc:creator>
                <dc:creator>Chi-Neu Tsai</dc:creator>
                <dc:creator>Wei-Chen Lee</dc:creator>
                <dc:creator>Miin-Fu Chen</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2013, null:136</dc:source>
        <dc:date>2013-06-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-11-136</dc:identifier>
                                <prism:require>/content/figures/1477-7819-11-136-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>136</prism:startingPage>
        <prism:publicationDate>2013-06-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/11/1/135">
        <title>Bronchioloalveolar carcinoma as a second malignancy in a pediatric osteosarcoma survivor: case report</title>
        <description>Background:
Primary lung cancer is extremely rare in children, while secondary malignancies reportedly develop in 2% to 3% of pediatric osteosarcoma survivors.Case presentationA 14-year-old girl was found to have two pulmonary lesions on computed tomography. These tumors had developed 1 year after osteosarcoma surgery. Segmentectomy of right segment 1 and wedge resection of right segment 9 were performed. Both lesions were completely resected and postoperative histopathological examination revealed metastasis of osteosarcoma and bronchioloalveolar carcinoma, respectively.
Conclusion:
Bronchioloalveolar carcinoma may present as a solitary pulmonary lesion indistinguishable from a metastatic lesion and should be included in the differential diagnosis of pulmonary lesions in survivors of pediatric cancer. Thus, pulmonary lesions identified in these patients should be biopsied or resected to establish a histological diagnosis.</description>
        <link>http://www.wjso.com/content/11/1/135</link>
                <dc:creator>Masayuki Okui</dc:creator>
                <dc:creator>Taichiro Goto</dc:creator>
                <dc:creator>Yuichiro Hayashi</dc:creator>
                <dc:creator>Robert Nakayama</dc:creator>
                <dc:creator>Mitsutomo Kohno</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2013, null:135</dc:source>
        <dc:date>2013-06-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-11-135</dc:identifier>
                                <prism:require>/content/figures/1477-7819-11-135-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>135</prism:startingPage>
        <prism:publicationDate>2013-06-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/11/1/134">
        <title>Sequential preoperative hepatic vein embolization after portal vein embolization for extended left hepatectomy in colorectal liver metastases</title>
        <description>Background:
The role of portal vein embolization to increase future liver remnant (FLR) is well-established in the treatment of colorectal liver metastases. However, the role of hepatic vein embolization is unclear.Case report: A patient with colorectal liver metastases received neoadjuvant chemotherapy prior to attempted resection. At the time of resection his tumor appeared to invade the left and middle hepatic vein, requiring an extended left hepatectomy including segments five and eight. Post-operatively, he underwent sequential left portal vein embolization followed by left hepatic vein embolization and finally, middle hepatic vein embolization. Hepatic vein embolization was performed to increase the FLR as well as to allow collateral drainage of the FLR to develop. A left trisectionectomy was then performed and no evidence of postoperative liver congestion or morbidity was found.
Conclusion:
Sequential portal vein embolization and hepatic vein embolization for extended left hepatectomy may be considered to increase FLR and may prevent right hepatic congestion after sacrificing the middle vein.</description>
        <link>http://www.wjso.com/content/11/1/134</link>
                <dc:creator>Gitonga Munene</dc:creator>
                <dc:creator>Robyn Parker</dc:creator>
                <dc:creator>John Larrigan</dc:creator>
                <dc:creator>Jason Wong</dc:creator>
                <dc:creator>Francis Sutherland</dc:creator>
                <dc:creator>Elijah Dixon</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2013, null:134</dc:source>
        <dc:date>2013-06-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-11-134</dc:identifier>
                                <prism:require>/content/figures/1477-7819-11-134-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>134</prism:startingPage>
        <prism:publicationDate>2013-06-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/11/1/133">
        <title>Clinicopathological analysis of colorectal cancer: a comparison between emergency and elective surgical cases</title>
        <description>Background:
Approximately 15 to 30% of colorectal cancers present as an emergency, most often as obstruction or perforation. Studies report poorer outcome for patients who undergo emergency compared with elective surgery, both for their initial hospital stay and their long-term survival. Advanced tumor pathology and tumors with unfavorable histologic features may provide the basis for the difference in outcome. The aim of this study was to compare the clinical and pathologic profiles of emergency and elective surgical cases for colorectal cancer, and relate these to gender, age group, tumor location, and family history of the disease. The main outcome measure was the difference in morphology between elective and emergency surgical cases.
Methods:
In total, 976 tumors from patients treated surgically for colorectal cancer between 2004 and 2006 in Stockholm County, Sweden (8 hospitals) were analyzed in the study. Seventeen morphological features were examined and compared with type of operation (elective or emergency), gender, age, tumor location, and family history of colorectal cancer by re-evaluating the histopathologic features of the tumors.
Results:
In a univariate analysis, the following characteristics were found more frequently in emergency compared with elective cases: multiple tumors, higher American Joint Committee on Cancer (AJCC), tumor (T) and node (N) stage, peri-tumor lymphocytic reaction, high number of tumor-infiltrating lymphocytes, signet-ring cell mucinous carcinoma, desmoplastic stromal reaction, vascular and perineural invasion, and infiltrative tumor margin (P&lt;0.0001 for AJCC stage III to IV, N stage 1 to 2/3, and vascular invasion). In a multivariate analysis, all these differences, with the exception of peri-tumor lymphocytic reaction, remained significant (P&lt;0.0001 for multiple tumors, perineural invasion, infiltrative tumor margin, AJCC stage III, and N stage 1 to 2/3).
Conclusions:
Colorectal cancers that need surgery as an emergency case generally show a more aggressive histopathologic profile and a more advanced stage than do elective cases. Essentially, no difference was seen in location, and therefore it is likely there would be no differences in macro-environment either. Our results could indicate that colorectal cancers needing emergency surgery belong to an inherently specific group with a different etiologic or genetic background.</description>
        <link>http://www.wjso.com/content/11/1/133</link>
                <dc:creator>Sam Ghazi</dc:creator>
                <dc:creator>Elisabeth Berg</dc:creator>
                <dc:creator>Annika Lindblom</dc:creator>
                <dc:creator>Ulrik Lindforss</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2013, null:133</dc:source>
        <dc:date>2013-06-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-11-133</dc:identifier>
                                <prism:require>/content/figures/1477-7819-11-133-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>133</prism:startingPage>
        <prism:publicationDate>2013-06-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
